SE7903240L - Anvendning av antiostrogener och antigonadotropt verkande antiandrogner for profylaktisk och terapeutisk behandling av prostatahyperplasi - Google Patents

Anvendning av antiostrogener och antigonadotropt verkande antiandrogner for profylaktisk och terapeutisk behandling av prostatahyperplasi

Info

Publication number
SE7903240L
SE7903240L SE7903240A SE7903240A SE7903240L SE 7903240 L SE7903240 L SE 7903240L SE 7903240 A SE7903240 A SE 7903240A SE 7903240 A SE7903240 A SE 7903240A SE 7903240 L SE7903240 L SE 7903240L
Authority
SE
Sweden
Prior art keywords
prostate hyperplasia
antiostrogenes
antigonadotroptic
prophylatic
drugs
Prior art date
Application number
SE7903240A
Other languages
Unknown language ( )
English (en)
Other versions
SE441977B (sv
Inventor
F Neumann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SE7903240L publication Critical patent/SE7903240L/sv
Publication of SE441977B publication Critical patent/SE441977B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE7903240A 1978-04-17 1979-04-11 Medel for profylaktisk och terapeutisk behandling av prostatahyperplasi pa basis av en blandning av viss antiostrogen och viss antigonadotropt verkande antiandrogen SE441977B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782817157 DE2817157A1 (de) 1978-04-17 1978-04-17 Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie

Publications (2)

Publication Number Publication Date
SE7903240L true SE7903240L (sv) 1979-10-18
SE441977B SE441977B (sv) 1985-11-25

Family

ID=6037493

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7903240A SE441977B (sv) 1978-04-17 1979-04-11 Medel for profylaktisk och terapeutisk behandling av prostatahyperplasi pa basis av en blandning av viss antiostrogen och viss antigonadotropt verkande antiandrogen

Country Status (13)

Country Link
US (1) US4310523A (sv)
JP (1) JPS5513261A (sv)
AU (1) AU528179B2 (sv)
BE (1) BE875634A (sv)
CA (1) CA1134271A (sv)
CH (1) CH641679A5 (sv)
DE (1) DE2817157A1 (sv)
GB (1) GB2018591B (sv)
IT (1) IT1119733B (sv)
LU (1) LU81153A1 (sv)
NL (1) NL7901961A (sv)
SE (1) SE441977B (sv)
ZA (1) ZA791797B (sv)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
WO1985002543A1 (en) * 1983-12-12 1985-06-20 Kaszynski Edwin G Hair growth modification
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
WO1990008555A1 (en) 1989-01-27 1990-08-09 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
DE69033020T2 (de) * 1989-07-07 1999-08-05 Endorecherche Inc Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2170400A1 (en) * 1994-06-27 1996-01-04 M. Frederick Hawthorne Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
WO1996040150A1 (en) * 1995-06-07 1996-12-19 Merck & Co., Inc. Treatment and prevention of prostatic disease
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1094798A2 (en) * 1998-03-11 2001-05-02 Endorecherche Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
EP1324754A1 (en) * 2000-07-05 2003-07-09 AstraZeneca AB Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
EA022208B1 (ru) * 2008-10-10 2015-11-30 Тева Вимен'С Хелс, Инк. Способы лечения вазомоторных симптомов у кастрированных пациентов с раком предстательной железы низкими дозами ципротерона ацетата
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076823A (en) * 1961-07-03 1963-02-05 Syntex Corp Process for the production of 6-chloro-3-keto-deta steroid compounds
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
DE2817157A1 (de) 1979-10-25
NL7901961A (nl) 1979-10-19
GB2018591A (en) 1979-10-24
AU528179B2 (en) 1983-04-21
BE875634A (fr) 1979-10-17
CA1134271A (en) 1982-10-26
IT7921854A0 (it) 1979-04-13
IT1119733B (it) 1986-03-10
LU81153A1 (de) 1979-06-19
JPS5513261A (en) 1980-01-30
SE441977B (sv) 1985-11-25
JPS645007B2 (sv) 1989-01-27
CH641679A5 (de) 1984-03-15
US4310523A (en) 1982-01-12
AU4560479A (en) 1979-10-25
GB2018591B (en) 1982-09-08
ZA791797B (en) 1980-11-26

Similar Documents

Publication Publication Date Title
SE7903240L (sv) Anvendning av antiostrogener och antigonadotropt verkande antiandrogner for profylaktisk och terapeutisk behandling av prostatahyperplasi
FI801614A (fi) Farmaceutiskt preparat i form av en polyakrylatfilm
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
TR18896A (tr) 1-fenil-2-triazolil-etil eter tuerevleri bunlarin hazirlanisina ait usul ve bunlarin fungisidler olarak kullanilmalari
ES2135703T3 (es) Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina.
PL203249A1 (pl) Przyrzad kosmetyczny do pielegnacji dermatologicznej przy pomocy mieszaniny pary wodnej i ozonu
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
US3395236A (en) Composition comprising oleic acid, polyethylene glycol, and gelating for treating nail infections
JPS5218813A (en) Plasters for the relief of cutaneous diseases
IT8019711A0 (it) Composizioni da usarsi come cosmetici e procedimento per lapreparazione dei loro ingredienti attivi.
IT1151009B (it) Derivati del 5h-furanone-2 e del 3h-diidrofuranone-2,loro procedimento di preparazione e loro applicazione terapeutica
Kohn et al. The effect of fractionated X-ray dosage upon the mouse testis. I. Maximum weight loss following 80 to 240 r given in 2 to 5 fractions during 1 to 4 days
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
SE7910300L (sv) Farmaceptisk komposition for behandling av neoplastiska sjukdomar och forfarande for dess framstellning
JPS554383A (en) Toilet composition for oily skin and hair treatment*its active compound and its manufacture
AR228434A1 (es) Procedimiento para obtener un producto para ser aplicado como agente activo en composiciones cosmeticas o para el tratamiento de dermatitis y procedimiento para preparar composiciones cosmeticas o farmaceuticas que lo incluyen como agente activo
SE7808138L (sv) Pyranokromonderivat och terapeutisk komposition innehallande detsamma for behandling av allergiska sjukdomar
JPS5562014A (en) Aqueous poultice having no skin irritation effect
IT7948786A0 (it) Derivati del 6,7 benzomorfano loro preparazione e loro applicazione in terapeutica
IT7825497A0 (it) Derivati di 1,2,4-ossadiazolo, loro preparazione e loro applicazione in terapia.
SE7604993L (sv) Forfarande och anordning for framstellning av desinfekterat, lagerbestendigt och i huvudsak luktlost och biologiskt aktivt jordforbettringsmaterial
EG14024A (en) Pharmaceutical compositions and their use in the profyloxis and or treatment of certain diseases
IT1113322B (it) Agente per attirare insetti composito,per i maschi della nottua del cavolo e procedimento per preparare i suoi principi attivi
JPS5553268A (en) Novel substituted benzamide*its manufacture and urogenital organ obstruction therapeutic drug as active ingredient thereof
NO146398C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme n1-glucufuranosid-6-yl-n3-nitrosourinstoffer

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7903240-5

Effective date: 19921108

Format of ref document f/p: F